Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New York State Psychiatric Institute
With
Eli Lilly and Company
This Open Pilot Study will assess whether Duloxetine is effective for patients with Atypical Features. 20 patients having Major Depressive Disorder with Atypical Features or Dysthymic Disorder will receive Duloxetine in open fashion for 8 weeks. Dose will begin with 20 mg/d and increase to PDR maximal dose of 120 mg/d, if tolerated.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DSM-IV Major Depression or Dysthymia with Atypical Features
Age 18-65
Physically healthy
HAMD(24) \> 14
You may not be if
Prior experience with Duloxetine
History of Psychosis or Bipolar Disorder, Borderline Personality Disorder
Unstable medical disorder; any history of Epilepsy
Currently taking medication that can interact with Duloxetine
Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
Serious suicidal ideation judged at least somewhat likely to be acted upon or require hospitalization
Current (past two weeks) use of psychoactive medication (four weeks for Fluoxetine)
Pregnancy
Currently breast feeding
Fecund women failing to use acceptable birth control
Refractory Depression (defined as failure to respond to one or more adequate trials of marketed antidepressants \[i.e., \>=2/3 PDR maximum dose for at least 4 weeks\] during current episode)
Serious suicidal ideation, recent (past six months) suicidal activity, any life-time history of serious suicide attempt (e.g., admitted to ICU, any duration of coma)
